Perfume compositions – Perfume compositions – With preservative – stabilizer – or fixative
Reexamination Certificate
2000-11-21
2008-08-12
Allen, Marianne P. (Department: 1647)
Perfume compositions
Perfume compositions
With preservative, stabilizer, or fixative
C530S397000
Reexamination Certificate
active
07410941
ABSTRACT:
Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
REFERENCES:
patent: 4377513 (1983-03-01), Sugimoto et al.
patent: 4703008 (1987-10-01), Lin
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 4835260 (1989-05-01), Shoemaker
patent: 5457089 (1995-10-01), Fibi et al.
patent: 5547933 (1996-08-01), Lin
patent: 5571787 (1996-11-01), O'Brien et al.
patent: 5614184 (1997-03-01), Sytkowski et al.
patent: 5618698 (1997-04-01), Lin
patent: 5621080 (1997-04-01), Lin
patent: 5661125 (1997-08-01), Strickland
patent: 5696080 (1997-12-01), O'Brien
patent: 5700909 (1997-12-01), O'Brien
patent: 5714459 (1998-02-01), O'Brien
patent: 5756349 (1998-05-01), Lin
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5835382 (1998-11-01), Wilson et al.
patent: 5856298 (1999-01-01), Strickland
patent: 5888772 (1999-03-01), Okasinski et al.
patent: 5955422 (1999-09-01), Lin
patent: 6165783 (2000-12-01), Weiss et al.
patent: 5-246885 (1993-09-01), None
patent: WO 95/05465 (1995-02-01), None
patent: WO 97/18318 (1997-05-01), None
patent: WO 97/32895 (1997-12-01), None
patent: WO 98/10650 (1998-03-01), None
patent: WO 98/18926 (1998-05-01), None
patent: WO 00/35475 (2000-06-01), None
patent: WO 01/82952 (2001-11-01), None
patent: WO 01/82953 (2001-11-01), None
Friedman et al. Erythropoietin in Diabetic Macular Edema and Renal Insufficiency. American Journal of Kidney Disease, Jul. 26(1):202-8 (1995).
Bernaudin et al., 1999, “A potential role for erythropoietin in focal permanent cerebral ischemia in mice”, J. Cereb. Blood Flow Metab. 19:643-651.
Bondy, 1995, “The relaxation of oxidative stress and hyperexcitation to neurological disease”, Proc. Soc. Exp. Biol. Med. 208:337-345.
Brines et al., 2000, “Erythropoietin crosses the blood-brain barrier to -protect against experimental brain injury”, Proc. Natl. Acad. Sci. USA 97:10526-10531.
Campana et al., 1998, “Identification of a neurotrophic sequence in erythropoietin”, Int. J. Mol. Med. 1:235-241.
Digicaylioglu et al. 1995, “Localization of specific erythropoietin binding sites in defined areas of the mouse brain.”, Proc. Natl. Acad. Sci. USA 92:3717-3720.
Dipaolo et al., 1992, “Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment”, ASAIO J. 38:M477-M480.
Grimm et al., 1990, “Improvement of brain function in hemodialysis patients treated with erythropoietin”, Kidney Intl. 38:480-486.
Hefti, 1997, “Pharmacology of neurotrophic factors”, Annu. Rev. Pharmacol. Toxicol. 37:239-267.
Hengemihle et al., 1996, “Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice”, Physiol. Behav. 59:153-156.
Hirakata et al., 1992, “CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO”, Am. J. Physiol. 262:F737-F743.
Juul et al., 1998, “Erythropoietin and erythropoietin receptor in the developing human central nervous system”, Pediatr. Res. 43:40-49.
Konishi et al., 1993, “Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo”, Brain Res. 609:29-35.
Kopf et al., 1994, “Memory-improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.”, Behav. Neural Biol. 62:237-243.
Latini et al., 1998, “Comparative efficacy of a DA2/α2 agoinst and a β-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion”, J. Cardiovasc. Pharmacol. 31:601-608.
Li et al., 1998, “A single pre-training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor”, Neurosci. 85:785-794.
Lipinski et al., 1995, “Nerve growth factor facilitates conditioned taste aversion learning in normal rats”, Brain Res. 692:143-153.
Liu et al., 1997, “Regulated human erythropoietin receptor expression in mouse brain”, J. Biol. Chem. 272:32395-32400.
Liu et al., 1994, “Tissue specific expression of human erythropoietin receptor in transgenic mice”, Devel. Biol. 166:159-169.
Marrero et al., 1998, “Erythropoietin receptor-operated Ca2+channels: activation by phospholipase C-γ1”, Kidney Intl. 53:1259-1268.
Marsh et al., 1991, “rHuEPO treatment improves brain and cognitive function of anemic dialysis patients”, Kidney Intl. 39:155-163.
Marti et al., 1997, “Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain”, Kidney Intl. 51:416-418.
Marti et al., 1996, “Erythropoietin gene expression in human, monkey and murine brain”, Eur. J. Neurosci. 8:666-676.
Masuda et al., 1997, “Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes”, Brain Res. 746:63-70.
Masuda et al., 1994, “A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes”, J. Biol. Chem. 269:19488-19493.
Masuda et al., 1993, “Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells”, J. Biol. Chem. 268:11208-11216.
Morishita et al., 1997, “Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death”, Neurosci. 76:105-116.
Moss and Scholey, 1996, “Oxygen administration enhances memory formation in healthy young adults”, Psychopharmacol. 124:255-260.
Nakamura et al., 1998, “Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients”, Am. J. Med. Sci. 315:199-201.
Nissenson et al., 1991, “Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects”, Ann. Int. Med. 114:402-416.
Nissenson, 1989, “Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life”, Sem. Nephrol. 9(suppl. 2):25-31.
Orgen, 1989, “Monitoring considerations in recombinant human erythropoietin therapy”, Sem. Nephrol. 9(suppl. 2):12-15.
Pardridge, 1997, “Drug delivery to the brain”, J. Cerebral Blood Flow Metab. 17:713-731.
Pardridge et al., 1991, “Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo”, J. Pharmacol. Exp. Ther. 27:66-70.
Poduslo et al., 1994, “Macromolecular premeability across the blood-nerve and blood-brain barriers”, Proc. Natl. Acad. Sci. USA 91:5705-5709.
Prendergast et al., 1997, “Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion”, Pharmacol. Biochem. Behav. 57:347-352.
Rose and Audus,
Brines Michael
Cerami Anthony
Cerami Carla
Allen Marianne P.
Deberry Regina M
Jones Day
The Kenneth S. Warren Institute, Inc.
LandOfFree
Methods for treatment of neurodegenerative conditions by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of neurodegenerative conditions by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of neurodegenerative conditions by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3999239